<DOC>
	<DOCNO>NCT00216216</DOCNO>
	<brief_summary>Patients relapse chemotherapy-refractory SCLC dismal prognosis . Unfortunately , available treatment result durable response . Pemetrexed well-tolerated agent , active NSCLC . Since chemotherapy agent , active NSCLC , usually also active SCLC , trial examine efficacy activity pemetrexed palliative setting</brief_summary>
	<brief_title>Pemetrexed Patients With Chemosensitive Chemoresistant Relapsed Small Cell Lung Cancer</brief_title>
	<detailed_description>OUTLINE : This multi-center study . - Pemetrexed 500 mg/m2 i.v . q 3 wks All patient also receive folic acid 350-1000 mcg . po daily begin approximately 1 week prior first dose pemetrexed continue completion pemetrexed , Vitamin B12 1000 mcg . IM every 9 week begin approximately 1 week prior first dose pemetrexed continue completion pemetrexed , dexamethasone 4 mg po bid day , day , day follow treatment pemetrexed Chest x-ray perform prior cycle ( disease assessment image perform ) order ensure patient rapidly progress . Cycles repeat every 3 week 6 cycle PD intolerable side effect . Performance Status : ECOG 0 , 1 , 2 Life Expectancy : Not specify Hematopoietic : - WBC &gt; 3000/mm3 - ANC &gt; 1500/mm3 - Platelet count &gt; 100,000/mm3 - Hemoglobin &gt; 8 g/dL Hepatic : - Bilirubin &lt; 1.0 X upper limit normal - Aspartate aminotransferase ( AST , SGOT ) &lt; 2.5 x upper limit normal . AST may &lt; 5 x upper limit normal patient liver metastasis Renal : - Creatinine clearance &gt; 45 ml/ min ( Cockcroft-Gault ) Cardiovascular : - No unstable uncompensated cardiovascular condition Pulmonary : - No unstable uncompensated respiratory condition</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histological cytological proof neuroendocrine cancer ( include small cell cancer site [ include lung ] poorly differentiate neuroendocrine cancer lung ( unidimensionally ) measurable disease per RECIST criterion Chemoresistant chemosensitive disease Patients must receive treatment least one 2 prior chemotherapy regimen , include one regimen contain platinum agent Radiation therapy must complete radiation least 14 day prior register protocol therapy , toxicity due radiation must recover &lt; grade 1 baseline prior registration Negative pregnancy test No clinically significant infection judge treat investigator No symptomatic CNS metastasis No radiation &gt; 25 % marrow contain space No previous treatment pemetrexed No uncontrolled pleural effusion No current breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>